Short Description: Hyperimmune intravenous immunoglobulin doesn't help COVID-19 patients: Study
Hyperimmune intravenous immunoglobulin doesn't help COVID-19 patients: Study
Washington [US], January 30 : The combination of remdesivir plus a highly concentrated solution of antibodies that neutralize SARS-CoV-2 is not more effective than remdesivir alone for treating adults hospitalised with COVID-19, according to recent research.
The study has been published in the 'The Lancet Journal'.
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, sponsored and funded the trial, called Inpatient Treatment with Anti-Coronavirus Immunoglobulin, or ITAC. The trial was conducted by the NIAID-funded International Network for Strategic Initiatives in Global HIV Trials (INSIGHT).
Mark Polizzotto, M.D., PhD, head of the Clinical Hub for Interventional Research at the College of Health & Medicine of The Australian National University in Canberra, led the trial.
The antibody solution tested in the ITAC trial was anti-coronavirus hyperimmune intravenous immunoglobulin or hIVIG. The antibodies in anti-coronavirus hIVIG came from the liquid portion of blood, or plasma, donated by healthy people who had recovered from COVID-19.
These antibodies were highly purified and concentrated so that the anti-coronavirus hIVIG consistently contained several times more SARS-CoV-2 neutralizing antibodies than typically found in the plasma of people who have recovered from COVID-19.
"In our quest to find safe and effective treatments for COVID-19, we had hoped that adding anti-coronavirus hIVIG to a remdesivir regimen would give the immune system a boost to help suppress the virus early in the course of hospitalization," said NIAID Director Anthony S. Fauci, M.D.
"Unfortunately, the ITAC trial demonstrated that this strategy did not improve the health of adults hospitalized with COVID-19 and may be harmful to a certain subset of patients. Studies testing this strategy in non-hospitalized adults earlier in the course of infection are underway," he added.
( Details and picture courtesy ANI, the content is auto-generated from the feed.)
Please follow us on Telegram for all the latest updates.
